Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Aberrant Huntingtin interacting protein 1 in lymphoid malignancies.

Bradley SV, Smith MR, Hyun TS, Lucas PC, Li L, Antonuk D, Joshi I, Jin F, Ross TS.

Cancer Res. 2007 Sep 15;67(18):8923-31.

2.

Huntingtin interacting protein 1 is a novel brain tumor marker that associates with epidermal growth factor receptor.

Bradley SV, Holland EC, Liu GY, Thomas D, Hyun TS, Ross TS.

Cancer Res. 2007 Apr 15;67(8):3609-15.

3.

Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer.

Bradley SV, Oravecz-Wilson KI, Bougeard G, Mizukami I, Li L, Munaco AJ, Sreekumar A, Corradetti MN, Chinnaiyan AM, Sanda MG, Ross TS.

Cancer Res. 2005 May 15;65(10):4126-33.

4.

Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-kappaB, p53, bax, and p27 levels.

Tucker CA, Kapanen AI, Chikh G, Hoffman BG, Kyle AH, Wilson IM, Masin D, Gascoyne RD, Bally M, Klasa RJ.

Mol Cancer Ther. 2008 Apr;7(4):749-58. doi: 10.1158/1535-7163.MCT-07-0302. Epub 2008 Mar 28.

5.

Huntingtin interacting protein 1 Is a clathrin coat binding protein required for differentiation of late spermatogenic progenitors.

Rao DS, Chang JC, Kumar PD, Mizukami I, Smithson GM, Bradley SV, Parlow AF, Ross TS.

Mol Cell Biol. 2001 Nov;21(22):7796-806.

6.

TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas.

Honma K, Tsuzuki S, Nakagawa M, Tagawa H, Nakamura S, Morishima Y, Seto M.

Blood. 2009 Sep 17;114(12):2467-75. doi: 10.1182/blood-2008-12-194852. Epub 2009 Jul 16.

7.

Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival.

Rao DS, Hyun TS, Kumar PD, Mizukami IF, Rubin MA, Lucas PC, Sanda MG, Ross TS.

J Clin Invest. 2002 Aug;110(3):351-60.

8.

Altered receptor trafficking in Huntingtin Interacting Protein 1-transformed cells.

Rao DS, Bradley SV, Kumar PD, Hyun TS, Saint-Dic D, Oravecz-Wilson K, Kleer CG, Ross TS.

Cancer Cell. 2003 May;3(5):471-82.

9.

Functional interplay of p53 and Mus81 in DNA damage responses and cancer.

Pamidi A, Cardoso R, Hakem A, Matysiak-Zablocki E, Poonepalli A, Tamblyn L, Perez-Ordonez B, Hande MP, Sanchez O, Hakem R.

Cancer Res. 2007 Sep 15;67(18):8527-35.

10.

Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity.

Böll B, Eltaib F, Reiners KS, von Tresckow B, Tawadros S, Simhadri VR, Burrows FJ, Lundgren K, Hansen HP, Engert A, von Strandmann EP.

Clin Cancer Res. 2009 Aug 15;15(16):5108-16. doi: 10.1158/1078-0432.CCR-09-0213. Epub 2009 Aug 11.

11.

Structural abnormalities in spermatids together with reduced sperm counts and motility underlie the reproductive defect in HIP1-/- mice.

Khatchadourian K, Smith CE, Metzler M, Gregory M, Hayden MR, Cyr DG, Hermo L.

Mol Reprod Dev. 2007 Mar;74(3):341-59.

PMID:
16967501
12.

The NFATc1 transcription factor is widely expressed in white cells and translocates from the cytoplasm to the nucleus in a subset of human lymphomas.

Marafioti T, Pozzobon M, Hansmann ML, Ventura R, Pileri SA, Roberton H, Gesk S, Gaulard P, Barth TF, Du MQ, Leoncini L, Möller P, Natkunam Y, Siebert R, Mason DY.

Br J Haematol. 2005 Feb;128(3):333-42. Erratum in: Br J Haematol. 2005 Apr;129(1):162. Marafiot, Teresa [corrected to Marafioti, Teresa].

PMID:
15667535
14.

Protein expression pattern distinguishes different lymphoid neoplasms.

Fujii K, Kondo T, Yokoo H, Yamada T, Matsuno Y, Iwatsuki K, Hirohashi S.

Proteomics. 2005 Nov;5(16):4274-86.

PMID:
16206328
15.
16.

Degenerative phenotypes caused by the combined deficiency of murine HIP1 and HIP1r are rescued by human HIP1.

Bradley SV, Hyun TS, Oravecz-Wilson KI, Li L, Waldorff EI, Ermilov AN, Goldstein SA, Zhang CX, Drubin DG, Varela K, Parlow A, Dlugosz AA, Ross TS.

Hum Mol Genet. 2007 Jun 1;16(11):1279-92. Epub 2007 Apr 23.

17.

TRAF1 is involved in the classical NF-kappaB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells.

Guo F, Sun A, Wang W, He J, Hou J, Zhou P, Chen Z.

Mol Immunol. 2009 Aug;46(13):2441-8. doi: 10.1016/j.molimm.2009.05.178. Epub 2009 Jun 21.

PMID:
19540595
18.

Mechanisms and consequences of constitutive NF-κB activation in B-cell lymphoid malignancies.

Nagel D, Vincendeau M, Eitelhuber AC, Krappmann D.

Oncogene. 2014 Dec 11;33(50):5655-65. doi: 10.1038/onc.2013.565. Epub 2014 Jan 27. Review.

PMID:
24469030
19.

Block of T cell development in P53-deficient mice accelerates development of lymphomas with characteristic RAG-dependent cytogenetic alterations.

Haines BB, Ryu CJ, Chang S, Protopopov A, Luch A, Kang YH, Draganov DD, Fragoso MF, Paik SG, Hong HJ, DePinho RA, Chen J.

Cancer Cell. 2006 Feb;9(2):109-20.

20.

Alteration of SMRT tumor suppressor function in transformed non-Hodgkin lymphomas.

Song L, Zlobin A, Ghoshal P, Zhang Q, Houde C, Weijzen S, Jiang Q, Nacheva E, Yagan D, Davis E, Galiegue-Zouitina S, Catovsky D, Grogan T, Fisher RI, Miele L, Coignet LJ.

Cancer Res. 2005 Jun 1;65(11):4554-61.

Items per page

Supplemental Content

Write to the Help Desk